BBNX — Beta Bionics Income Statement
0.000.00%
Last trade - 00:00- $475.10m
- $692.90m
- $65.12m
Annual income statement for Beta Bionics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.179 | 12 | 65.1 |
| Cost of Revenue | |||
| Gross Profit | — | 6.31 | 35.9 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 66 | 47.8 | 110 |
| Operating Profit | -65.8 | -35.9 | -45.3 |
| Total Net Non Operating Interest Income / Expense | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -64.8 | -44.1 | -54.8 |
| Net Income After Taxes | -64.8 | -44.1 | -54.8 |
| Net Income Before Extraordinary Items | |||
| Net Income | -64.8 | -44.1 | -54.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -64.8 | -44.1 | -54.8 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.51 | -1.03 | -1.28 |
| Dividends per Share |